Recent advances in subtyping tumors of the central nervous system using molecular data

Expert Review of Molecular Diagnostics

Volumn 17, Issue 1, 2017, Pages 83-94

  Schittenhelm, Jens ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

1p 19q codeletion; ATRX; BRAF; Glioma; H3F3A; IDH; TERT

Indexed keywords

ADULT; ASTROCYTOMA; CANCER CLASSIFICATION; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHOROID PLEXUS TUMOR; EPENDYMOMA; GLIOBLASTOMA; GLIONEURONAL TUMOR; HUMAN; PINEAL BODY TUMOR; REVIEW; BRAIN TUMOR; CLASSIFICATION; GENETICS; OLIGODENDROGLIOMA;

BRAIN NEOPLASMS; EPENDYMOMA; GLIOBLASTOMA; HUMANS; OLIGODENDROGLIOMA;

EID: 85006165727     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2017.1266259     Document Type: Review

References (75)

1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.
2. Nayak L, Lee EQ, Wen PY., Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54.
3. Halani SH. Brat DJ:defining neoplastic diseases differently:an emerging paradigm from The Cancer Genome Atlas lower-grade gliomas project. Mol Cell Oncol. 2016;3(2):e1074333.
4. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary. Acta Neuropathol. 2016;131(6):803–820.• Comprehensive summary of the latest changes in brain tumor classification.
5. Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited:2005 to 2009. Cancer. 2016;122(14):2206–2215.
6. Ellis HP, Greenslade M, Powell B, et al. Current challenges in glioblastoma:intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol. 2015;5:251.
7. Sundar SJ, Hsieh JK, Manjila S, et al. The role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6.
8. Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–910.
9. Jorgensen JT. The importance of predictive biomarkers in oncology drug development. Expert Rev Mol Diagn. 2016;16(8):807–809.
10. Schittenhelm J, Skardelly M. Molecular advances in glioblastoma neuropathology. In:Amit A, editor. Neurooncology newer developments. ed. Rijeka:Intech; 2016. p. 3–26. doi:10.5772/62670.
11. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772.
12. Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917–930.
13. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.•• Seminal paper demonstrating recurrent somatic mutations in glioblastoma, defining a prognostically relevant tumor subgroup.
14. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487–494.
15. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327.
16. van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–1526.
17. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907–915.
18. Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407–417.
19. Rodriguez FJ, Vizcaino MA. Lin MT:recent advances on the molecular pathology of glial neoplasms in children and adults. J Mol Diagn. 2016;18(5):620–634.
20. Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016;16(7):737–749.
21. Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316–327.
22. Kim J, Lee IH, Cho HJ, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28(3):318–328.
23. Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016;48(7):768–776.
24. Dupati A, Gill L. Vemurafenib:background, patterns of resistance, and strategies to combat resistance in melanoma. Medical Student Research Journal. 2014;3(Winter):36–43.
25. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
26. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma:the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926.
27. Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016;75(1):4–18.
28. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561–571.
29. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061–1068. doi:10.1038/nature07385.•• This Cancer Genome Atlas Research Network study shows that adult glioblastoma are molecularly highly variable and that divergent actionable driver mutations are present.
30. Ortega A, Nuno M, Walia S, et al. Treatment and survival of patients harboring histological variants of glioblastoma. J Clin Neurosci. 2014;21(10):1709–1713.
31. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685–698.
32. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age:a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474.
33. Idbaih A, Ducray F, Dehais C, et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. Plos One. 2012;7(10):e45950.
34. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–722.
35. Ebrahimi A, Skardelly M, Bonzheim I, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun. 2016;4(1):60.
36. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma:long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343.
37. Grimm SA. Chamberlain MC:anaplastic astrocytoma. CNS Oncol. 2016;5(3):145–157.
38. Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival:a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873.
39. Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors:BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016;131(6):833–845.
40. Krishnatry R, Zhukova N, Guerreiro Stucklin AS, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma:a population-based study. Cancer. 2016;122(8):1261–1269.
41. Mesturoux L, Durand K, Pommepuy I, et al. Molecular analysis of tumor cell components in pilocytic astrocytomas, gangliogliomas, and oligodendrogliomas. Appl Immunohistochem Mol Morphol. 2016;24(7):496–500.
42. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118(3):401–405.
43. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17(14):4790–4798.
44. Brokinkel B, Peetz-Dienhart S, Ligges S, et al. A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas:age-related and mutually exclusive. [Corrected]. Neuropathol Appl Neurobiol. 2015;41(2):258–261.
45. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–612.
46. Roth JJ, Fierst TM, Waanders AJ, et al. Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status. J Neuropathol Exp Neurol. 2016;75(4):306–315.
47. Rodriguez FJ, Schniederjan MJ, Nicolaides T, et al. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol. 2015;129(4):609–610.
48. Chappe C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013;23(5):574–583.
49. Chamberlain MC. Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncol. 2016;5(1):27–29.
50. Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 1990;2016(65):91–101.
51. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
52. Venneti S, Santi M, Felicella MM. et al.:A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128(5):743–753.
53. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–450.
54. Gessi M, Capper D, Sahm F, et al. Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol. 2016;132(4):635–637.
55. Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 2016;131(1):137–146.
56. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231.•• Valuable paper demonstrating distinct molecular alterations in pediatric glioblastoma associated with specific anatomic locations.
57. Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015;129(5):669–678.
58. Fruhwald MC, Biegel JA, Bourdeaut F, et al. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016;18(6):764–778.
59. Wetmore C, Boyett J, Li S, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol. 2015;17(6):882–888.
60. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era:the current consensus. Acta Neuropathol. 2016;131(6):821–831.
61. Kaur K, Kakkar A, Kumar A, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice:a simplified approach. Brain Pathol. 2016;26(3):334–343.
62. Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the sonic hedgehog signaling pathway:review of smoothened and GLI inhibitors. Cancers. 2016;8:2.
63. Morfouace M, Shelat A, Jacus M, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 2014;25(4):516–529.
64. Spence T, Sin-Chan P, Picard D. et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128(2):291–303.
65. Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060–1072.•• Important paper showing that the majority of primitive neuroepithelial tumors can be assigned to existing entities based on molecular profiling and identification of four new embyronal tumor entities with distinct genetic alterations.
66. Kros JM. Grading of gliomas:the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70(2):101–109.
67. Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. 2014;506(7489):451–455.• This paper reports that ependymal brain tumors in the cerebrum contain a diagnostic fusion gene predicting clinical outcome.
68. Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011;20(3):384–399.
69. Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–743.
70. Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012;124(2):247–257.
71. Gajjar A, Pfister SM, Taylor MD, et al. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014;20(22):5630–5640.
72. Prabowo AS, van Thuijl HF, Scheinin I, et al. Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours. Neuropathol Appl Neurobiol. 2015;41(6):743–755.
73. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.• This paper shows that treatable BRAF point mutations are quite common in some brain tumor classes.
74. Zanello M, Pages M, Tauziede-Espariat A, et al. Clinical, imaging, histopathological and molecular characterization of anaplastic ganglioglioma. J Neuropathol Exp Neurol. 2016;75(10):971–980.
75. Rivera B, Gayden T, Carrot-Zhang J, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol. 2016;131(6):847–863.